PYXS Pyxis: Enterprise Value-to-Revenue Multiple

Public company logo of Pyxis Oncology Inc. (PYXS)

The GURU.Markets terminal displays the change in EV/Sales valuation, where the 14610.51 metric serves as the target level. The environmental responsibility of Pyxis Oncology, Inc. (PYXS) is evident in its strict control of laboratory waste and energy conservation. A transparent ADC drug pipeline and management's expertise in pharmaceutical partnerships form the business foundation, while a high reputation within the oncology community confirms the potential of innovative targeted antibodies.

Company Value to Revenue: Pyxis (PYXS) for 11/23/2025 - 11/20/2026

Pyxis - analytical breakdowns and key metrics (PYXS)

- share price and consensus valuation forecast:
Initial company analysis:Pyxis Oncology Inc. PYXS
Product sample of Pyxis Oncology Inc.

Analyzing the assets of Pyxis Oncology, Inc. (PYXS) requires an assessment of the market potential of its ADC platform. This enterprise value-to-revenue ratio measures the total value of the company, excluding debt, relative to its generated income. An increase in this metric signals inflated market expectations for targeted cancer therapy. An overly sharp spike in the multiple creates a risk of price correction, while stable dynamics confirm the fair capitalization of the biotech project.

Competitor analysis for Pyxis Oncology, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP